Gritstone bio, Inc. (GRTS) on Tuesday said it has entered into a funding deal of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance Gritstone's second-generation Covid-19 vaccine program against SARS-CoV-2 Variants.
As per the deal, CEPI will fund a Phase 1 study evaluating the company's second-generation Covid-19 vaccine program, CORAL's SAM (self-amplifying mRNA) vaccine in naïve, convalescent, and HIV+ patients. The study is expected to initiate before the end of 2021. The funding will also support pre-clinical studies, scale-up and formulation development to enable more stable drug product.
Together with the CEPI supported study, four different vaccine candidates will be evaluated to establish optimal dosing and antigenic content for the CORAL program in young individuals, the elderly, the previously vaccinated, and the immunocompromised, Gritstone said.
A Phase 1 study of Gritstone's second-generation Covid-19 vaccine candidate, CORAL, sponsored by National Institute of Allergy and Infectious Disease (NIAID) in healthy people and as a booster for previously vaccinated volunteers is ongoing.
"CEPI is planning for the longer-term management of COVID-19 by investing in vaccines to address the threat of variants, and I'm pleased to work with Gritstone to advance the development of this innovative vaccine candidate which can be made globally accessible through COVAX if it is proven to be safe and effective," said Richard Hatchett, CEO of CEPI.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.